Dr. Filip Janku, MD
Claim this profileMD Anderson Cancer Center
Studies Solid Tumors
Studies Cancer
9 reported clinical trials
18 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
PD-1 positive
2Cancer
Stage IV
Stage III
Affiliated Hospitals
Clinical Trials Filip Janku, MD is currently running
IDE196 Combinations
for Solid Tumors
This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.
Recruiting1 award Phase 1 & 29 criteria
BCA101 + Pembrolizumab
for Cancer
This trial is testing BCA101, a new drug that targets specific cancer growth proteins, in patients with advanced cancers that haven't responded to other treatments. The drug works by blocking proteins that help the cancer grow and spread.
Recruiting1 award Phase 17 criteria
More about Filip Janku, MD
Clinical Trial Related6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Filip Janku, MD has experience with
- Atezolizumab
- Everolimus
- Sirolimus
- Temsirolimus
- Vorinostat
- FF-10850 Topotecan Liposome Injection
Breakdown of trials Filip Janku, MD has run
Solid Tumors
Cancer
Squamous Cell Carcinoma
Head and Neck Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Filip Janku, MD specialize in?
Filip Janku, MD focuses on Solid Tumors and Cancer. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Filip Janku, MD currently recruiting for clinical trials?
Yes, Filip Janku, MD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Filip Janku, MD has studied deeply?
Yes, Filip Janku, MD has studied treatments such as Atezolizumab, Everolimus, Sirolimus.
What is the best way to schedule an appointment with Filip Janku, MD?
Apply for one of the trials that Filip Janku, MD is conducting.
What is the office address of Filip Janku, MD?
The office of Filip Janku, MD is located at: MD Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the MD Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.